Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
TNYA(NASDAQ:TNYA) SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 pm ET.
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
TNYA(NASDAQ:TNYA) Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
TNYASOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 11:30 am ET.
Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target
TNYATenaya Therapeutics Q1 EPS $(0.24) Misses $(0.20) Estimate
TNYAHC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target
TNYATenaya Therapeutics Reveals Interim Data from RIDGE Natural History And Seroprevalence Study Of Adults With PKP2-Associated ARVC At Heart Rhythm 2025
TNYAHC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target
TNYATenaya Therapeutics Announces Late Breaker Presentation Of New Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201 At American College Of Cardiology Annual Meeting
TNYATenaya Therapeutics Approves Restructuring Plan; Restructuring Plan To Reduce Cash Expenses; Restructuring Plan To Extend Cash Runway Into H2 2026; To Reduce Workforce Under Restructuring Plan; To Incur $1.6M-$2.7M In Restructuring Charges; Expects To Rec
TNYATenaya Announces Preclinical Data For TN-201 Gene Therapy In Nature Communications: MYBPC3 Gene Replacement Shows Dose-Dependent MyBP-C Protein Increase, Reverses Left Ventricular Hypertrophy; TN-201 In Phase 1b/2 Trial For MYBPC3-Associated Hypertrophic
TNYATenaya Therapeutics Files For Mixed Shelf Offering Of Up To $300M
TNYATenaya Therapeutics Announced Presentation Of TN-201 Gene Therapy Data For MYBPC3-Associated Hypertrophic Cardiomyopathy At ACC 2025 In Chicago; Includes 1-Year Patient Assessments From MyPEAK-1 Phase 1b/2 Trial
TNYACanaccord Genuity Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $6
TNYAMorgan Stanley Maintains Overweight on Tenaya Therapeutics, Lowers Price Target to $5
TNYAHC Wainwright & Co. Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $5
TNYATenaya Therapeutics Q4 2024 GAAP EPS $(0.28) Beats $(0.31) Estimate
TNYAReported Earlier, Tenaya Therapeutics Prices $52.5M Public Offering Of 75M Units, Strengthening Pipeline For TN-201 & TN-401
TNYATenaya Therapeutics Announced Intention To Offer Common Stock, Series A & B Warrants
TNYAHC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $18 Price Target
TNYATenaya Therapeutics Announces Progress In Gene Therapies TN-201 And TN-401 For Cardiomyopathies; Dosing Started In Cohort 2 Of MyPEAK-1 Phase 1b/2 Trial; Cohort 1 Data Expected H1 2025; Initial Data From RIDGE-1 Trial Of TN-401 Expected In H2 2025
TNYATenaya Therapeutics Q3 EPS $(0.30) Beats $(0.36) Estimate
TNYATenaya Thearpeutics Reports Will Present Preclinical Data On Gene Therapy Programs, Platform Capabilities At American Society Of Gene And Cell Therapy Meeting May 17, 2022 At 5:30 p.m. EDT
TNYA